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Abstract
Background: Schizophrenia is a chronic and disabling disease that presents with delusions and hallucinations.
Auditory hallucinations are usually expressed as voices speaking to or about the patient. Previous studies have
examined the effect of repetitive transcranial magnetic stimulation (TMS) over the temporoparietal cortex on
auditory hallucinations in schizophrenic patients. Our aim was to explore the potential effect of deep TMS, using
the H coil over the same brain region on auditory hallucinations.
Patients and methods: Eight schizophrenic patients with refractory auditory hallucinations were recruited, mainly
from Beer Ya’akov Mental Health Institution (Tel Aviv university, Israel) ambulatory clinics, as well as from other
hospitals outpatient populations. Low-frequency deep TMS was applied for 10 min (600 pulses per session) to the
left temporoparietal cortex for either 10 or 20 sessions. Deep TMS was applied using Brainsway’s H1 coil apparatus.
Patients were evaluated using the Auditory Hallucinations Rating Scale (AHRS) as well as the Scale for the
Assessment of Positive Symptoms scores (SAPS), Clinical Global Impressions (CGI) scale, and the Scale for
Assessment of Negative Symptoms (SANS).
Results: This preliminary study demonstrated a significant improvement in AHRS score (an average reduction of
31.7% ± 32.2%) and to a lesser extent improvement in SAPS results (an average reduction of 16.5% ± 20.3%).
Conclusions: In this study, we have demonstrated the potential of deep TMS treatment over the temporoparietal
cortex as an add-on treatment for chronic auditory hallucinations in schizophrenic patients. Larger samples in a
double-blind sham-controlled design are now being preformed to evaluate the effectiveness of deep TMS
treatment for auditory hallucinations.
Trial registration: This trial is registered with clinicaltrials.gov (identifier: NCT00564096).
Introduction
Schizophrenia is usually accompanied by reality distor-
tion followed by frequent delusions and hallucinations.
Hallucinations may be both visual and auditory, while the
latter is more frequent. Auditory hallucinations are
usually expressed by voices speaking to or about the
patient [1]. The biochemical mechanisms behind auditory
hallucinations (AHs) remain elusive. Generally, AHs may
be considered to stem from a default monitoring of inner
states. As a result, the individual mislabels the inner
speech as non-self [2].
Auditory hallucinations are reported by 50% to 70% of
patients with schizophrenia, and the majority of cases are
successfully treated with antipsychotic medications.
However, 25% to 30% of hallucinating schizophrenic
patients are refractory to antipsychotic medications, and
therefore patients suffer associated distress, functional
disability, lack of behavioral control [3] and violent beha-
vior [4]. It has also been known to be a contributing fac-
tor in up to 25% of cases of serious suicide attempts [5].
Transcranial magnetic stimulation (TMS) is a non-
invasive tool that stimulates nerve cells in superficial
areas of the brain. TMS, which was first introduced in
* Correspondence: odedaruna@gmail.com
1Beer Ya’akov Mental Health Center affiliated to Sackler School of Medicine,
University of Tel Aviv, Tel Aviv, Israel
Full list of author information is available at the end of the article
Rosenberg et al. Annals of General Psychiatry 2011, 10:3
http://www.annals-general-psychiatry.com/content/10/1/3
© 2011 Rosenberg et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.1985 [6], induces a magnetic field that can produce a
substantive electrical field in the brain causing depolari-
zation of nerve cells, which results in the stimulation or
disruption of local brain activity. TMS may be applied
as a single stimulus, or repeated many times per seconds
(rTMS), with variation in intensity, site and orientation
of the magnetic field [7]. The first report of rTMS treat-
ment for auditory hallucinations was described in 1999
by Hoffman et al. [8]. In that study, rTMS was applied
over the left temporoparietal cortex of three patients
over 4 days (for 4, 8, 12 and 16 min). Hoffman et al.
reported an improvement in auditory hallucination
severity in those patients, as rated on a visual analogue
scale (VAS) [8]. Since then, several studies have used
rTMS to treat auditory hallucinations in schizophrenic
patients, targeting almost exclusively the left temporo-
parietal cortex, with mixed results [3,4,7,9,10]. The phy-
siological basis of the rTMS-induced beneficial effect on
auditory hallucinations is not well understood, but may
reflect reduced pyramidal neuron excitability or neuro-
plasticity changes analogous to those associated with
long-term depression [3,4,10]. Imaging studies of
patients with of auditory hallucinations demonstrated
increased blood flow in the speech perception areas of
the brain, such as the superior temporal cortex of the
dominant hemisphere and the superior temporal cortex
bilaterally [11], and therefore, neuronal hyperactivity in
these areas has been associated with AHs. Overactiva-
tion of the left temporoparietal cortex, which is critical
to speech perception and is easily accessible to rTMS,
has been implicated to be involved in the onset of audi-
tory hallucinations [10]. In a 2003 study, Hoffman et al.
detected improvement primarily in frequency and atten-
tional salience of hallucinations, which were also asso-
ciated with modest overall clinical improvement, but
with no negative effects of rTMS on cognition [4].
The H1 coil, used for deep TMS, has been shown to
be effective in the treatment of major depression
[12-14]. Deep TMS coils are designed to maximize the
electrical field in deep brain tissues by the summation
of separate fields projected into the skull from several
points around its periphery [15]. The device is planned
to minimize the accumulation of electrical charge on
the surface of the brain, which can give rise to an elec-
trostatic field that might reduce the magnitude of the
induced electric field both at the surface and inside, and
reduce the depth penetration of the induced electric
field [16]. Deep TMS could be more effective than
rTMS due to the larger and deeper spread of field it can
produce [15]. In our study we examined the efficacy of
deep TMS over the left temporoparietal cortex for the
treatment of auditory hallucinations in refractory schizo-
phrenic patients.
Methods
Participants
Eight participants (an equal number of males and
females) were recruited to this study via outpatient
clinics all over Israel. All patients gave written informed
consent to take part in the study, which was approved
by the Beer-Ya’akov Mental Health Center Ethics Com-
mittee and the Israeli Ministry of Health. Inclusion cri-
teria were: age between 18 to 65, ability to sign an
informed consent, meeting Diagnostic and Statistical
Manual of Mental Disorders, fourth edition text revision
(DSM-IV-TR) criteria for schizophrenia/schizoaffective
disorder, experiencing auditory hallucinations at least
five times per day, and use of a stable antipsychotic
medication for at least 1 month prior to enrollment.
Participant ages ranged between 28 to 62 years (average
28.8 years). Six patients were diagnosed with schizophre-
nia and two were diagnosed with schizoaffective disorder.
Seven were outpatients and one an inpatient. Hallucina-
tions had persisted for an average of 11 years, despite
adequate trials with an average of 4.75 (SD ± 1.9) anti-
psychotic medications prior to study entry. The auditory
hallucinations of six patients were also resistant to treat-
ment with an average dose of 470 mg/day clozapine
(SD ± 75.8 mg). All participants were on antipsychotic
medication during the study, with their dosage of medica-
tion being kept stable throughout the study. Demo-
graphic data for all patients is presented in Table 1.
Exclusion criteria for deep TMS are essentially the
same as those for rTMS, including: neurosurgery, brain
trauma, patients suffering from chronic medical condi-
tions of any sort, history of current hypertension, history
of seizure or heart convulsion, history of epilepsy or
seizure in first degree relatives, history of head injury,
history of any metal objects in the head area (other than
the mouth), known history of any metallic particles in
the eye, implanted cardiac pacemaker or any intracar-
diac lines, implanted neurostimulators, surgical clips or
any medical pumps, history of frequent or severe head-
aches, history of migraine, history of hearing loss,
known history of cochlear implants, history of drug
abuse or alcoholism, pregnancy (tested by b-human
chorionic gonadotropin test) or not using a reliable
method of birth control, systemic and metabolic disor-
ders, inadequate communication skills or being under
custodial care.
Deep TMS procedure
We performed the treatments with Brainsway’sH 1c o i l
(Brainsway, Jerusalem, Israel), which was checked in a
safety study with healthy volunteers [17], and in a clinical
study for the treatment of major depression (Levkovitz
et al. [14]). The H1 coil detailed configuration and
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et al. [17]. Deep TMS was administered by a Brainsway’s
H1 coil, connected to a Magstim Rapid
2 stimulator (Mag-
stim, Whitland, UK). The resting motor threshold for
each participant was obtained by stimulation to the left
motor cortex, and defined as the minimum stimulator
output intensity that causes a motor response (that is,
twitching of the contralateral abductor policis brevis
(APB) muscle in the hand).
The coil was then moved 4.5 cm posteriorly and
6.5 cm laterally towards the left shoulder of the patient.
In this position, the maximal electric field produced by
the coil is at the left temporoparietal cortex (Figure 1).
Patients were treated with 10 min of deep H coil TMS
to the left temporoparietal cortex at a frequency of 1 Hz
with 110% motor threshold for either 10 or 20 working
days (Five days a week and two days weekend interval)
(Table 2).
Patient assessment
Diagnoses were made by trained psychiatrists using a
semistructured clinical interview based on DSM-IV-TR
criteria [Structured Clinical Interview for DSM-IV Axis I
Disorders, version 2 (SCID-II)], during which patients
main demographic and clinical characteristics were col-
lected. Each patient was evaluated within 24 h prior to
TMS study session, and post treatment within 24 h of the
last session, using the Auditory Hallucinations Rating
Scale (AHRS) developed by Hoffman et al. [4], the Scale
for the Assessment of Positive Symptoms scores (SAPS;
[10]), the Clinical Global Impressions (CGI) scale, and the
Scale for the Assessment of Negative Symptoms (SANS).
Table 1 Demographic data
Patient
no.
Sex Age Status Education,
years
Diagnosis Age of
disease
onset
Number of
past
hospitalizations
Time elapsed since
present episode of
auditory hallucinations
started, years
No. of antipsychotic
medications to which
auditory hallucinations
were resistant
1 M 30 Outpatient 11 Schizophrenia 19 4 11 6
2 F 62 Inpatient 13 Schizoaffective 53 3 9 6
3 M 58 Outpatient 10 Schizophrenia 18 >10 29 2
4 F 47 Outpatient 12 Schizoaffective 25 >10 5 5
5 M 28 Day care 12 Schizophrenia 27 2 1 6
6 M 37 Outpatient 13 Schizophrenia 20 7 18 7
7 F 54 Outpatient 10 Schizophrenia 42 7 12 4
8 F 55 Outpatient 9 Schizophrenia 27 2 5 2
Figure 1 Electric field distribution maps of the H1 coil when placed during stimulation over the left temporoparietal cortex, at an
intensity of 110% of a typical abductor policis brevis (APB) motor threshold. The images are based on electric field measurements in a
phantom head model filled with saline water at physiological concentration.
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other rating scales within 1 day after the last treatment
session, and at 1 week and 1 month follow-up sessions.
Results
A total of 5 patients were first treated for 10 days with deep
H coil TMS over the left temporoparietal cortex at a fre-
quency of 1 Hz for 10 min using an intensity of 110% of the
motor threshold. For those patients, average AHRS at the
end of treatment improved by 34.5% (SD ± 38.2%) compare
to baseline, including one patient for whom auditory hallu-
cination ceased completely for 2 days. Average SAPS
improved by 23.1% (SD ± 18. 9%), and there was also
minor reduction of 11.2% (SD ± 10.4%) in CGI score and
9.2% reduction (SD ± 10%) in SANS score. However, dur-
ing follow-up all results gradually returned to baseline
levels and the effect of hallucination amelioration was lost
almost completely (Figure 2). Therefore, the number of ses-
sions was increased for the next 3 patients to 20 sessions.
In these patients (patients 6-8), average AHRS was
improved at the end of treatment by 27.8% (SD ± 26.2%),
average SAPS score improved by 13.75% (SD ± 12.3%),
and there was also a minor reduction of 6.5% (SD ± 7.3)
in SANS score. One patient did not improve and was lost
to follow-up after treatment. However, in contrast to the
first five patients, in the remaining two patients symptom
scores kept improving such that at the 1 month follow-
up the average change in AHRS and SAPS scores reached
a reduction of 42.6% and 17.9%, respectively (Figure 3).
Auditory hallucination scale paired t test values for all
eight patients at baseline were as follows: P = 0.039 at
24 h follow-up, P = 0.004 at 1 week follow-up and
P = 0.029 at 1 month follow-up (Table 3).
Side effects
Treatment was very well tolerated. One patient experi-
enced headache after one session, which subsided after
administration of 500 mg of paracetamol.
Discussion
All patients but one improved with deep TMS, and one
patient’s auditory hallucinations ceased completely.
The results at the end of treatment were better in the
group receiving 10 sessions; however, this group’s symp-
tom scores gradually returned to baseline levels during
follow-up. Conversely, in 2 out of 3 patients receiving
20 sessions, we observed less improvement at the end of
treatment but a further improvement during follow-up,
reaching a considerable reduction of auditory hallucina-
tions at the 1 month follow-up. Considering the resis-
tance of auditory hallucinations to treatment in these
patients (failure of 4.75 trials of antipsychotic medica-
tions on average), this study may mark a direction for
future explorations using deep TMS, in which sham-
controlled studies would be crucial to demonstrate
efficacy.
An electroconvulsive therapy study of 253 patients
with schizophrenia found greater severity of baseline
Table 2 Treatment parameters
Patient no. Motor threshold Pulses per session No. of sessions
1 110% 600 10
2 110% 600 10
3 110% 600 10
4 110% 600 10
5 110% 600 10
6 110% 600 20
7 110% 600 20
8 110% 600 20
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Figure 2 Average scores of Auditory Hallucinations Rating Scale
(AHRS), Scale for the Assessment of Positive Symptoms (SAPS)
and Scale for Assessment of Negative Symptoms (SANS) (with
standard error of mean (SEM)) 1 day before treatment
(baseline), 1 day after last session (end of treatment), 1 week
after last session and at 1 month after last session in the 10-
session group.
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Figure 3 Average scores of Auditory Hallucinations Rating
Scale (AHRS), Scale for the Assessment of Positive Symptoms
(SAPS) and Scale for Assessment of Negative Symptoms (SANS)
(with standard error of mean (SEM)) 1 day before treatment
(baseline), 1 day after last session (end of treatment), 1 week
after last session and at 1 month after last session in the 20-
session group.
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[18]. In our study we observed no correlation between
baseline negative symptoms as judged by SANS and
amelioration of auditory hallucinations. Loo et al. [19]
noted that examinations of individual-controlled trials
reveal that a substantial proportion of rTMS studies for
the treatment of auditory hallucinations did not find
rTMS superior to sham stimulations. The authors also
noted that although most trials have involved the
administration of rTMS to the left temporoparietal cor-
tex, it is far from conclusive that abnormalities asso-
ciated with auditory hallucinations are specific to the
left hemisphere [19]. There is some evidence that the
pathology of auditory hallucinations involves not only
the left hemisphere, but also the right one [11]. Accord-
ing to Vercammen et al., evidence from neuroimaging
studies suggests a potential for bilateral temporal cortex
involvement in the genesis of auditory hallucinations.
Left superior temporal areas are hypothesized to be
involved in speech perception during the hallucinations,
and the right temporal cortex may be more associated
with the processing of prosody and emotional salience,
which is often expressed in the derogatory and hostile
content of the hallucinations [20]. Schreiber et al., in a
c a s es t u d y ,s h o w e dt h a td a i l yr i g h tp r e f r o n t a lr T M Sf o r
20 days at 10 Hz frequency with 90% motor threshold
may induce a general clinical improvement in the brain
function of patients with schizophrenia [21]. The advan-
tage of left-sided or right-sided stimulation might be
individually determined, depending on the individual
underlying pathophysiology. rTMS shows the best
results when guided by functional MRI to areas of acti-
vation during hallucinations, whether in the left or right
hemisphere [22].
Limitations
The limitations of our study are the small number of
patients, lack of a sham control group, the rater not
being blind and the heterogeneity of treatment
(5 patients underwent 10 sessions while 3 underwent
20 sessions).
Conclusions
Our preliminary results showed a significant improve-
ment in our patient group. The small number of
patients in our study precludes a conclusion regarding
deep TMS efficacy, even though it marks a direction for
possible future studies. We believe that a future large-
scale, double-blind, sham-controlled study, targeting
various brain regions, could clarify the effectiveness of
deep TMS in the treatment of resistant auditory
hallucinations.
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